Sirolimus plus low-dose chemotherapy for high-risk childhood tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 1 year old and no older than 30 years when joining
- Your cancer must be a specific high-risk childhood solid tumor (and not a brain tumor or lymphoma)
- Your scans must show complete remission or only minimal remaining abnormalities after standard upfront treatment or relapse treatment
- You must have recovered from most past treatment side effects, and current labs must be strong enough (blood counts, kidneys, liver, and lungs if needed)
- You must be able to take the study meds safely with required restrictions on other medicines and pregnancy prevention
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a continuous, low-dose (“metronomic”) cancer medicine to help delay cancer coming back in children and young adults with certain sarcomas. You must have finished first-line treatment and currently be in remission, starting the study soon after treatment ends.
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial tests a new type of sirolimus (a targeted therapy) combined with antibody-drug conjugates (ADCs) for advanced solid tumors that haven't responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
This study tests a combination of two drugs, MM-398 and cyclophosphamide, for children and young adults whose cancer has come back or not responded to earlier treatment. The goal is to find the best dose and see how well it works against certain tumor types.
This trial tests a combination of three drugs (dinutuximab beta, irinotecan, and rapamycin) for people with bone cancers like osteosarcoma or Ewing sarcoma that have come back or not responded to treatment. The goal is to see if this combination can shrink or slow the tumors.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.